Literature DB >> 29545548

Kinase inhibitors: the road ahead.

Fleur M Ferguson1,2, Nathanael S Gray1,2.   

Abstract

Receptor tyrosine kinase signalling pathways have been successfully targeted to inhibit proliferation and angiogenesis for cancer therapy. However, kinase deregulation has been firmly demonstrated to play an essential role in virtually all major disease areas. Kinase inhibitor drug discovery programmes have recently broadened their focus to include an expanded range of kinase targets and therapeutic areas. In this Review, we provide an overview of the novel targets, biological processes and disease areas that kinase-targeting small molecules are being developed against, highlight the associated challenges and assess the strategies and technologies that are enabling efficient generation of highly optimized kinase inhibitors.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29545548     DOI: 10.1038/nrd.2018.21

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN: 1474-1776            Impact factor:   84.694


  269 in total

1.  Vinyl sulfone: a versatile function for simple bioconjugation and immobilization.

Authors:  Julia Morales-Sanfrutos; Javier Lopez-Jaramillo; Mariano Ortega-Muñoz; Alicia Megia-Fernandez; Francisco Perez-Balderas; Fernando Hernandez-Mateo; Francisco Santoyo-Gonzalez
Journal:  Org Biomol Chem       Date:  2009-12-11       Impact factor: 3.876

Review 2.  Immunobiology of the TAM receptors.

Authors:  Greg Lemke; Carla V Rothlin
Journal:  Nat Rev Immunol       Date:  2008-05       Impact factor: 53.106

3.  Chemical interrogation of the malaria kinome.

Authors:  Emily R Derbyshire; Vanessa Zuzarte-Luís; Andreia D Magalhães; Nobutaka Kato; Paul C Sanschagrin; Jinhua Wang; Wenjun Zhou; Chandrasekhar V Miduturu; Ralph Mazitschek; Piotr Sliz; Maria M Mota; Nathanael S Gray; Jon Clardy
Journal:  Chembiochem       Date:  2014-08-08       Impact factor: 3.164

Review 4.  DYRK1A kinase inhibitors with emphasis on cancer.

Authors:  A Ionescu; F Dufrasne; M Gelbcke; I Jabin; R Kiss; D Lamoral-Theys
Journal:  Mini Rev Med Chem       Date:  2012-11       Impact factor: 3.862

Review 5.  Neuroprotective Mechanisms Mediated by CDK5 Inhibition.

Authors:  Gohar Mushtaq; Nigel H Greig; Firoz Anwar; Fahad A Al-Abbasi; Mazin A Zamzami; Hasan A Al-Talhi; Mohammad A Kamal
Journal:  Curr Pharm Des       Date:  2016       Impact factor: 3.116

6.  Cutting Edge: RIP1 kinase activity is dispensable for normal development but is a key regulator of inflammation in SHARPIN-deficient mice.

Authors:  Scott B Berger; Viera Kasparcova; Sandy Hoffman; Barb Swift; Lauren Dare; Michelle Schaeffer; Carol Capriotti; Michael Cook; Joshua Finger; Angela Hughes-Earle; Philip A Harris; William J Kaiser; Edward S Mocarski; John Bertin; Peter J Gough
Journal:  J Immunol       Date:  2014-05-12       Impact factor: 5.422

7.  Ranibizumab combined with low-dose sorafenib for exudative age-related macular degeneration.

Authors:  Teresa Diago; Jose S Pulido; Julian R Molina; Lucienne C Collett; Thomas P Link; Edwin H Ryan
Journal:  Mayo Clin Proc       Date:  2008-02       Impact factor: 7.616

8.  CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation.

Authors:  Jiehui Deng; Eric S Wang; Russell W Jenkins; Shuai Li; Ruben Dries; Kathleen Yates; Sandeep Chhabra; Wei Huang; Hongye Liu; Amir R Aref; Elena Ivanova; Cloud P Paweletz; Michaela Bowden; Chensheng W Zhou; Grit S Herter-Sprie; Jessica A Sorrentino; John E Bisi; Patrick H Lizotte; Ashley A Merlino; Max M Quinn; Lauren E Bufe; Annan Yang; Yanxi Zhang; Hua Zhang; Peng Gao; Ting Chen; Megan E Cavanaugh; Amanda J Rode; Eric Haines; Patrick J Roberts; Jay C Strum; William G Richards; Jochen H Lorch; Sareh Parangi; Viswanath Gunda; Genevieve M Boland; Raphael Bueno; Sangeetha Palakurthi; Gordon J Freeman; Jerome Ritz; W Nicholas Haining; Norman E Sharpless; Haribabu Arthanari; Geoffrey I Shapiro; David A Barbie; Nathanael S Gray; Kwok-Kin Wong
Journal:  Cancer Discov       Date:  2017-11-03       Impact factor: 38.272

9.  Design of reversible, cysteine-targeted Michael acceptors guided by kinetic and computational analysis.

Authors:  Shyam Krishnan; Rand M Miller; Boxue Tian; R Dyche Mullins; Matthew P Jacobson; Jack Taunton
Journal:  J Am Chem Soc       Date:  2014-09-02       Impact factor: 15.419

10.  Targeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapy.

Authors:  Hong Jiang; Samarth Hegde; Brett L Knolhoff; Yu Zhu; John M Herndon; Melissa A Meyer; Timothy M Nywening; William G Hawkins; Irina M Shapiro; David T Weaver; Jonathan A Pachter; Andrea Wang-Gillam; David G DeNardo
Journal:  Nat Med       Date:  2016-07-04       Impact factor: 53.440

View more
  216 in total

1.  Sunitinib Treatment-elicited Distinct Tumor Microenvironment Dramatically Compensated the Reduction of Myeloid-derived Suppressor Cells.

Authors:  Sheng-Yung Fu; Chun-Chieh Wang; Fang-Hsin Chen; Ching-Fang Yu; Ji-Hong Hong; Chi-Shiun Chiang
Journal:  In Vivo       Date:  2020 May-Jun       Impact factor: 2.155

Review 2.  Challenges and implications of genomics for T-cell lymphomas.

Authors:  Eric D Jacobsen; David M Weinstock
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2018-11-30

3.  Discovery of Covalent CDK14 Inhibitors with Pan-TAIRE Family Specificity.

Authors:  Fleur M Ferguson; Zainab M Doctor; Scott B Ficarro; Christopher M Browne; Jarrod A Marto; Jared L Johnson; Tomer M Yaron; Lewis C Cantley; Nam Doo Kim; Taebo Sim; Matthew J Berberich; Marian Kalocsay; Peter K Sorger; Nathanael S Gray
Journal:  Cell Chem Biol       Date:  2019-03-28       Impact factor: 8.116

4.  Leveraging Atropisomerism to Obtain a Selective Inhibitor of RET Kinase with Secondary Activities toward EGFR Mutants.

Authors:  Sean T Toenjes; Valeria Garcia; Sean M Maddox; Gregory A Dawson; Maria A Ortiz; F Javier Piedrafita; Jeffrey L Gustafson
Journal:  ACS Chem Biol       Date:  2019-08-29       Impact factor: 5.100

Review 5.  Protein-protein interaction modulators: advances, successes and remaining challenges.

Authors:  Lloyd Mabonga; Abidemi Paul Kappo
Journal:  Biophys Rev       Date:  2019-07-12

6.  The dynamic conformational landscape of the protein methyltransferase SETD8.

Authors:  Shi Chen; Rafal P Wiewiora; Fanwang Meng; Nicolas Babault; Anqi Ma; Wenyu Yu; Kun Qian; Hao Hu; Hua Zou; Junyi Wang; Shijie Fan; Gil Blum; Fabio Pittella-Silva; Kyle A Beauchamp; Wolfram Tempel; Hualiang Jiang; Kaixian Chen; Robert J Skene; Yujun George Zheng; Peter J Brown; Jian Jin; Cheng Luo; John D Chodera; Minkui Luo
Journal:  Elife       Date:  2019-05-13       Impact factor: 8.140

7.  Systematic Characterization of Recurrent Genomic Alterations in Cyclin-Dependent Kinases Reveals Potential Therapeutic Strategies for Cancer Treatment.

Authors:  Weiwei Shan; Jiao Yuan; Zhongyi Hu; Junjie Jiang; Yueying Wang; Nicki Loo; Lingling Fan; Zhaoqing Tang; Tianli Zhang; Mu Xu; Yutian Pan; Jiaqi Lu; Meixiao Long; Janos L Tanyi; Kathleen T Montone; Yi Fan; Xiaowen Hu; Youyou Zhang; Lin Zhang
Journal:  Cell Rep       Date:  2020-07-14       Impact factor: 9.423

8.  From Proteomic Mapping to Invasion-Metastasis-Cascade Systemic Biomarkering and Targeted Drugging of Mutant BRAF-Dependent Human Cutaneous Melanomagenesis.

Authors:  Aikaterini F Giannopoulou; Athanassios D Velentzas; Athanasios K Anagnostopoulos; Adamantia Agalou; Nikos C Papandreou; Stamatia A Katarachia; Dimitra G Koumoundourou; Eumorphia G Konstantakou; Vasiliki I Pantazopoulou; Anastasios Delis; Maria T Michailidi; Dimitrios Valakos; Dimitris Chatzopoulos; Popi Syntichaki; Vassiliki A Iconomidou; Ourania E Tsitsilonis; Issidora S Papassideri; Gerassimos E Voutsinas; Polydefkis Hatzopoulos; Dimitris Thanos; Dimitris Beis; Ema Anastasiadou; George Th Tsangaris; Dimitrios J Stravopodis
Journal:  Cancers (Basel)       Date:  2021-04-22       Impact factor: 6.639

9.  Anti-tubercular activity of novel 4-anilinoquinolines and 4-anilinoquinazolines.

Authors:  Christopher R M Asquith; Neil Fleck; Chad D Torrice; Daniel J Crona; Christoph Grundner; William J Zuercher
Journal:  Bioorg Med Chem Lett       Date:  2019-07-10       Impact factor: 2.823

10.  Activating p53 and Inhibiting Superenhancers to Cure Leukemia.

Authors:  Brian Ball; Omar Abdel-Wahab
Journal:  Trends Pharmacol Sci       Date:  2018-12       Impact factor: 14.819

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.